KEYWAY Trademark

Trademark Overview


On Monday, December 6, 2021, a trademark application was filed for KEYWAY with the United States Patent and Trademark Office. The USPTO has given the KEYWAY trademark a serial number of 97157727. The federal status of this trademark filing is REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED as of Sunday, January 28, 2024. This trademark is owned by Alloy Therapeutics, Inc.. The KEYWAY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Conducting scientific research for others in the fields of pharmaceutical discovery, pharmaceutical research and development, pharmaceuticals, biotechnology, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics; Conducting scientific research for others in the fields of engineered proteins, T cell receptors, artificial T cell receptors, antibody-based mimics of T cell receptors (TCR mimics), chimeric antigen receptors, biopharmaceuticals, biotherapeutics, immunotherapeutics, cell-based therapeutics, T cell therapeutics, genetic engineering, genome modulation, and genome editing; Conducting scientific research for others in the field of cellular immunotherapy programs utilizing engineered T cells
keyway

General Information


Serial Number97157727
Word MarkKEYWAY
Filing DateMonday, December 6, 2021
Status654 - REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED
Status DateSunday, January 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesConducting scientific research for others in the fields of pharmaceutical discovery, pharmaceutical research and development, pharmaceuticals, biotechnology, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics; Conducting scientific research for others in the fields of engineered proteins, T cell receptors, artificial T cell receptors, antibody-based mimics of T cell receptors (TCR mimics), chimeric antigen receptors, biopharmaceuticals, biotherapeutics, immunotherapeutics, cell-based therapeutics, T cell therapeutics, genetic engineering, genome modulation, and genome editing; Conducting scientific research for others in the field of cellular immunotherapy programs utilizing engineered T cells

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, December 10, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAlloy Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events


Event DateEvent Description
Sunday, January 28, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, July 31, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, January 31, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, January 26, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, January 26, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, January 26, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 3, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, August 3, 2022LETTER OF SUSPENSION E-MAILED
Wednesday, August 3, 2022SUSPENSION LETTER WRITTEN
Tuesday, August 2, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 1, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 1, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 1, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 1, 2022NON-FINAL ACTION E-MAILED
Tuesday, February 1, 2022NON-FINAL ACTION WRITTEN
Friday, January 21, 2022ASSIGNED TO EXAMINER
Friday, December 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 9, 2021NEW APPLICATION ENTERED